News

The companies will make use of Genome-Wide SpliceArray (GWSA) platform by Exonhit to study AD molecular markers associated with clinical parameters. Exonhit’s SpliceArray platform is microarray design that

The company applies its patented Carboxyl Terminal Peptide (CTP) technology and its Reversible Pegylation technology to develop longer-acting, proprietary versions of already approved therapeutic proteins. The CTP technology

Under the acquisition, Shaanxi Weinan’s portfolio of 86 drugs and one health product will be added to the Shaanxi Aoxing’s current drug portfolio. Biostar Pharmaceutical Board chairman and

The controlled, randomized trial which enrolls 90 patients is designed to assess the overall survival as well as the safety and immune response. CRS-207 is based on Aduro’s

KRN5500 is a non-narcotic, non-opioid, analgesic agent produced by Streptomyces alanosinicus. According to the Phase II, double-blind, placebo-controlled, randomized, dose escalation study, KRN5500 showed significant improvement in the

The contract also supports the research on plasminogen activator (TPA) and Silabilin as MCM’s against sulfur mustard gas exposure. AEOL can also be used to treat pulmonary injuries

The new project which is worth $3.5m will lay emphasis on manufacturing pharmaceutical and medical device products. The company said the move has been made following a rise

Postherpetic neuralgia (PHN) is referred to the pain following healing of the rash associated with shingles. Gralise is available as a prescription drug in a 30-day starter pack,

The double-blind, placebo-controlled and randomized trial which enrolled 100 patients was designed to assess the efficacy and safety of the talactoferrin in patients with previously treated non-small cell